High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients
World Journal of GastroenterologyPublished 1 January 2010Open access
Jian-Cong Sun
Citations42
SJR quartileQ1
SJR score1.42
SNIP1.38
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
High expression level of EDIL3 predicts poor prognosis of HCC patients, and may be a potential target of antiangiogenic therapy for HCC.
Abstract
High expression level of EDIL3 predicts poor prognosis of HCC patients. EDIL3 may be a potential target of antiangiogenic therapy for HCC.
Keywords
Immunology and MicrobiologyBiochemistry, Genetics and Molecular Biology
CA A Cancer Journal for CliniciansGlobal cancer statistics
54,961 Citations2011Ahmedin Jemal, Freddie Bray +3 more
A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
CA A Cancer Journal for CliniciansGlobal Cancer Statistics, 2002
18,390 Citations2005Donald Maxwell Parkin, Freddie Bray +2 more
There are striking variations in the risk of different cancers by geographic area, most of the international variation is due to exposure to known or suspected risk factors related to lifestyle or environment, and provides a clear challenge to prevention.
The Lancet OncologyManagement of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009
416 Citations2009Donald Poon, Benjamin O. Anderson +10 more
This consensus statement reviews the available medical evidence for management of HCC in Asia, and gives treatment recommendations that are adapted to resource availability in this diverse region with disparate health-care delivery systems.
HepatologyTranscriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas†
339 Citations2006Jianhua Luo, Bao‐Guo Ren +10 more
It is found that HCC and adjacent non‐neoplastic cirrhotic tissue have considerable overlap in gene expression patterns compared to normal liver, and specific areas of the genome appear unstable in HCC.
HepatologyClinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver
323 Citations1998Osama N. El‐Assal, Akira Yamanoi +6 more
The MVD in HCC may be involved in the dismal prognosis of this tumor, and VEGF may be associated with the angiogenic process of the cirrhotic liver, but not with theAngiogenesis of HCC.
Journal of Clinical OncologyTumor Microvessel Density as a Predictor of Recurrence After Resection of Hepatocellular Carcinoma: A Prospective Study
287 Citations2002Ronnie Tung‐Ping Poon, Irene Oi‐Lin Ng +5 more
A high MVD-CD34 was predictive of early postresection recurrence in patients with HCCs < or = 5 cm and, therefore, may be a novel prognostic marker in this subset of patients.
Genes & DevelopmentCloning and characterization of developmental endothelial locus-1: An embryonic endothelial cell protein that binds the αvβ3 integrin receptor
247 Citations1998Chiaki Hidai, T Zupancic +12 more
Del1 is shown to be a matrix protein and to promote adhesion of endothelial cells through interaction with the αvβ3 integrin receptor and may function to regulate vascular morphogenesis or remodeling in embryonic development.
Cancer LettersAngiogenesis and antiangiogenic therapy in hepatocellular carcinoma
213 Citations2006Roberta Pang, Ronnie T.P. Poon
Current data suggest that vascular endothelial growth factor (VEGF) plays a critical role in angiogenesis of HCC, which is of great clinical significance because there is no existing effective systemic therapy for HCC.
The Anatomical RecordVascular Changes in Hepatocellular Carcinoma
207 Citations2008Zhen Yang, Ronnie T.P. Poon
Despite the fact that treatment of HCC remains a tough task due to lack of effective systemic therapy, antiangiogenic therapy has already entered clinical trials in HCC patients and sheds light on a promising novel treatment for this disease.
Journal of Cancer Research and Clinical OncologyMicrovessel density of hepatocellular carcinoma: its relationship with prognosis
120 Citations1999Hui‐Chuan Sun, Zhao–You Tang +4 more
The MVD level was not related to tumor size, capsule statuo, Edmondson's grade, α-fetoprotein level, associated cirrhosis, γ-glutamyltransferase and serum HBsAg status, and was an independent predicting factor of disease-free survival.
Journal of Clinical InvestigationNeovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1
117 Citations2003Jingping Zhong, Brian P. Eliceiri +7 more
Findings provide evidence for an angiogenic switch that can be initiated in the absence of exogenous growth factors and indicate that the angiogen matrix protein Del-1 may be a useful tool for the therapy of ischemic disease.
Microvascular ResearchThe Embryonic Angiogenic Factor Del1 Accelerates Tumor Growth by Enhancing Vascular Formation
89 Citations2002Yoshikazu Aoka, Frances L. Johnson +6 more
Data suggest that Del1 acts as an angiogenic factor in the context of solid tumor formation and that this increase in vascularization accelerates tumor growth through decreased apoptosis.
American Heart JournalResults from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease
79 Citations2007Paul Grossman, Farrell O. Mendelsohn +12 more
Journal of HepatologyThymidine phosphorylase (platelet-derived endothelial cell growth factor), microvessel density and clinical outcome in hepatocellular carcinoma
37 Citations1998Akitaka Yamamoto, Dipok Kumar Dhar +4 more
It is indicated that platelet-derived endothelial cell growth factor may not be a major regulator of angiogenesis of hepatocellular carcinoma, but this enzyme may play an important role in hepatocarcinogenesis cooperating with hepatitis C virus.
Journal of Biomedical ScienceDownregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer
32 Citations2008Xiaolong Zou, Haiquan Qiao +4 more
Downregulation of Del1 presents a potent therapeutic strategy to combat colon cancer and both Del1-shRNA and VEGF-sh RNA gene therapies exhibited anti-tumor activities and they also showed a synergistic effect in suppressing growth of colon tumors by anti-angiogenesis and anti-proliferation.
Brain ResearchDel-1 gene transfer induces cerebral angiogenesis in mice
30 Citations2008Yongfeng Fan, Wei Zhu +7 more
The data suggest that Del- 1 may participate in modulating cerebral angiogenesis, and that gene transfer of Del-1 may provide a novel and potent means for stimulating cerebralAngiogenesis.
European Journal of Cancer PreventionThe role of adhesion molecules, αvβ3, αvβ5 and their ligands in the tumor cell and endothelial cell adhesion
29 Citations2007Ji Xiao Niu, Wen Jian Zhang +6 more
The adhesion of tumor cells with Del-1 and L1 expression was higher in T3A than that in liver sinusoidal endothelial cells, and was significantly increased under hypoxic conditions, Interestingly, the tumor cell adherence could be inhibited by antibodies against &agr;v&bgr;3 and &agR;v-b Gr;5, but not by an antibody against intercellular adhesion molecule-1, suggesting that other receptors are involved.
Human Gene TherapyDesign of the Del-1 for Therapeutic Angiogenesis Trial (DELTA-1), a Phase II Multicenter, Double-Blind, Placebo-Controlled Trial of VLTS-589 in Subjects with Intermittent Claudication Secondary to Peripheral Arterial Disease
28 Citations2004Sanjay Rajagopalan, Jeffrey W. Olin +7 more
The novel aspects of the protocol include the usage of a Del-1 plasmid-polaxamer formulation to enhance gene transfer at doses that are an order of magnitude different than other comparable trials in a unique bilateral intramuscular dosing pattern to maximize transfection/clinical efficacy and general applicability to patients with PAD.
Journal of Pharmacy and PharmacologyBiodistribution and safety studies of hDel-1 plasmid-based gene therapy in mouse and rabbit models
25 Citations2004Abraham Quezada, Martha French +5 more
The results supported testing of hDel‐1 plasmid‐based gene therapy in phase I clinical trials as a potential gene therapy for peripheral arterial disease in man and in mice and rabbits.
Journal of Clinical InvestigationNeovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1
16 Citations2003Jingping Zhong, Brian P. Eliceiri +7 more
The Anatomical Record Part A Discoveries in Molecular Cellular and Evolutionary BiologyOverexpression of the <i>Del1</i> gene causes dendritic branching in the mouse mesentery
10 Citations2005Chiaki Hidai, Masatoshi Kawana +7 more
The phenotype of mice overexpressing Del1 suggests the existence of a tissue-specific mechanism for branching morphogenesis in the mesentery.
Journal of Biomedical ScienceDownregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer
3 Citations2008Xiaolong Zou, Haiquan Qiao +4 more
Journal of Surgical ResearchAnti-apoptotic effects of the angiogenic factor Del1 on endothelial cells
2 Citations2006Z. Wang, Michael T. Longaker +1 more